吉非替尼联合异环磷酰胺、艾迪治疗晚期非小细胞肺癌的临床效果及对免疫功能、骨髓抑制的影响

目的 分析吉非替尼联合异环磷酰胺、艾迪治疗晚期非小细胞肺癌(NSCLC)的临床效果及对免疫功能、骨髓抑制的影响.方法 选取我院收治的晚期NSCLC患者92例,随机将其分为对照组和研究组,每组46例.对照组接受吉非替尼联合异环磷酰胺治疗,研究组接受吉非替尼联合异环磷酰胺、艾迪治疗.比较两组的治疗效果.结果 治疗后,研究组...

Clinical effect of gefitinib combined with ifosfamide and Aidi in the treatment of advanced non-small cell lung cancer and its influences on immune function and myelosuppression

Objective To analyze the clinical effect of gefitinib combined with ifosfamide and Aidi in the treatment of advanced non-small cell lung cancer(NSCLC)and its influences on immune function and myelosuppression.Methods A total of 92 patients with advanced NSCLC admitted in our hospital were selected and randomly divided into control group and study group,with 46 cases in each group.The control group was treated with gefitinib combined with ifosfamide,while the study group was treated with gefitinib combined with ifosfamide and Aidi.The therapeutic effects of the two groups were compared.Results After treatment,the CD3⁺,CD4⁺and CD8⁺of the study group were significantly better than those of the control group(P<0.05);the quality of life of the study group was significantly better than that of the control group(P<0.05);the incidence of myelosuppression in the study group was significantly lower than that in the control group(P<0.05);the total incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion Gefitinib combined with ifosfamide and Aidi has a significant effect in the treatment of patients with advanced NSCLC,it can improve immune function and reduce myelosuppression,which is worthy of clinical promotion.